Next gen I-O approaches: what will follow the PD-1s?

IMMUNO-ONCOLOGY INSIGHTS

Next gen I-O approaches: what will follow the PD-1s?

November 2020
Next gen I-O approaches: what will follow the PD-1s?

Expert Insight

DNA-encoded immunotherapeutics: ready for blast-off?

DNA-encoded immunotherapeutics: ready for blast-off?

Diana Guimet, Trevor RF Smith, Jeffrey M. Skolnik
1 December 2020
Read
Neoantigen vaccines for cancer: ready for primetime

Neoantigen vaccines for cancer: ready for primetime

A Perales-Puchalt, N Cooch, A Shende et al.
19 November 2020
Read
Gamma–delta T cells in immuno-oncology: opportunity for next generation immune modulators

Gamma–delta T cells in immuno-oncology: opportunity for next generation immune modulators

A Truneh, A De Gassart, P Frohna et al.
19 November 2020
Read

Innovator Insight

Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

Ilse Roodink, Patrick Ott, Nina Senutovitch
1 December 2020
Read

Interview

Reducing the complexity of bispecific antibody manufacture for cancer therapy

Reducing the complexity of bispecific antibody manufacture for cancer therapy

Sven Ante Lundberg
27 November 2020
Read
Keys to successful clinical translation of next-gen oncolytic virotherapies

Keys to successful clinical translation of next-gen oncolytic virotherapies

Jochen Stritzker
10 September 2020
Read